Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

203.84 -1.64 (-0.80%)
Streaming Delayed Price Updated: 10:33 AM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗
 
Via Benzinga
News headline image
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in... 
Via Benzinga
News headline image
Analyst Expectations for Alnylam Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? ↗
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin- 
Via Benzinga
News headline image
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug ↗
Shares skidded to their lowest point since September on the FDA's rejection. 
Via Investor's Business Daily
News headline image
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Growth Stocks That Could Rocket Higher Before the End of 2023 ↗
Potential approvals of new medicines expected soon could push these stocks through the roof. 
Via The Motley Fool
News headline image
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗
 
Via Benzinga
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects ↗
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. 
Via Benzinga
News headline image
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer ↗
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug. 
Via Investor's Business Daily
News headline image
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease ↗
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going ↗
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data. 
Via Benzinga
Topics Economy Stocks
News headline image
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates ↗
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. 
Via InvestorPlace
News headline image
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time, 
Via Benzinga
News headline image
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
News headline image
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.